RARA and acute myeloid leukemia: We initially restricted our analysis to CBFB::MYH11, RUNX1::RUNX1T1, PML::RARA, and NPM1c-mutated AML (without FLT3-ITD mutations), all of which are favorable-risk, as well as healthy donor CD34+ cell controls.